Clinical Proteomics:Article Title: Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.
Article Snippet: .. Nomenclature PAH Pulmonary arterial hypertension TGF-β Transforming growth factor beta BMPR2 Bone morphogenetic protein receptor type II PH Pulmonary hypertension nano-DDS Nanoparticle-mediated drug delivery systems ELPCs Endothelial-like progenitor cells mPAP Mean pulmonary artery pressure PASMCs Pulmonary artery smooth muscle cells ET-1 Endothelin-1 PDE5 Phosphodiesterase-5 sGC Soluble guanylate cyclase NO Nitric oxide RhoA The Ras homolog family member A ROCK Rho kinase ERAs Endothelin receptor antagonists PDE5i Phosphodiesterase-5 inhibitors SDF Sildenafl TAD Tadalafl FAD Fasudil MCT Monocrotaline EndoMT Endothelial-to-mesenchymal transition NPs Nanoparticles PLGA Poly-lactic/glycolic acid MMAD Mass median aerodynamic diameter RCRPC Respirable controlled-release polymeric colloids Cmax Maximum Plasma Concentration Tmax Time to reach maximum plasma concentration AUC0‐t Area under the plasma concentration–time curve from time zero to time t P(VS-VA)-gPLGA Poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly (lactide-co-glycolide) BALF Bronchoalveolar lavage fuid MOFs Metal-organic frameworks DSPE-PEG 1,2-Distearoyl-sn-glycero-3-phosphoethanolamineN-[methoxy (polyethylene glycol)] HPAH High pulmonary blood fow–associated pulmonary hypertension ELPCs Endothelial-like progenitor cells EPCs Endothelial progenitor cells BPS Beraprost PLA Poly(lactide) SuHx Sugen–hypoxia–normoxia Lips Liposomes EPR The enhanced permeability and retention efect LNPs Liposomal nanoparticles MRI Magnetic resonance imaging RVSP Right ventricular systolic pressure DOTAP 1,2-di-(9Z-octadecenoyl)-3-trimethylammoniumpropane ID1 Diferentiation 1 OVA Ovalbumin PDTC Pyrrolidine dithiocarbamate SA Stearic acid Canadian Respiratory Journal, 2026 15 of 23 7503, 2026, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1155/carj/8046858 by IN A SP - N E PA L , W iley O nline L ibrary on [10/04/2026]. ..
Concentration Assay:Article Title: Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.
Article Snippet: .. Nomenclature PAH Pulmonary arterial hypertension TGF-β Transforming growth factor beta BMPR2 Bone morphogenetic protein receptor type II PH Pulmonary hypertension nano-DDS Nanoparticle-mediated drug delivery systems ELPCs Endothelial-like progenitor cells mPAP Mean pulmonary artery pressure PASMCs Pulmonary artery smooth muscle cells ET-1 Endothelin-1 PDE5 Phosphodiesterase-5 sGC Soluble guanylate cyclase NO Nitric oxide RhoA The Ras homolog family member A ROCK Rho kinase ERAs Endothelin receptor antagonists PDE5i Phosphodiesterase-5 inhibitors SDF Sildenafl TAD Tadalafl FAD Fasudil MCT Monocrotaline EndoMT Endothelial-to-mesenchymal transition NPs Nanoparticles PLGA Poly-lactic/glycolic acid MMAD Mass median aerodynamic diameter RCRPC Respirable controlled-release polymeric colloids Cmax Maximum Plasma Concentration Tmax Time to reach maximum plasma concentration AUC0‐t Area under the plasma concentration–time curve from time zero to time t P(VS-VA)-gPLGA Poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly (lactide-co-glycolide) BALF Bronchoalveolar lavage fuid MOFs Metal-organic frameworks DSPE-PEG 1,2-Distearoyl-sn-glycero-3-phosphoethanolamineN-[methoxy (polyethylene glycol)] HPAH High pulmonary blood fow–associated pulmonary hypertension ELPCs Endothelial-like progenitor cells EPCs Endothelial progenitor cells BPS Beraprost PLA Poly(lactide) SuHx Sugen–hypoxia–normoxia Lips Liposomes EPR The enhanced permeability and retention efect LNPs Liposomal nanoparticles MRI Magnetic resonance imaging RVSP Right ventricular systolic pressure DOTAP 1,2-di-(9Z-octadecenoyl)-3-trimethylammoniumpropane ID1 Diferentiation 1 OVA Ovalbumin PDTC Pyrrolidine dithiocarbamate SA Stearic acid Canadian Respiratory Journal, 2026 15 of 23 7503, 2026, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1155/carj/8046858 by IN A SP - N E PA L , W iley O nline L ibrary on [10/04/2026]. ..
Proximity Ligation Assay:Article Title: Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.
Article Snippet: .. Nomenclature PAH Pulmonary arterial hypertension TGF-β Transforming growth factor beta BMPR2 Bone morphogenetic protein receptor type II PH Pulmonary hypertension nano-DDS Nanoparticle-mediated drug delivery systems ELPCs Endothelial-like progenitor cells mPAP Mean pulmonary artery pressure PASMCs Pulmonary artery smooth muscle cells ET-1 Endothelin-1 PDE5 Phosphodiesterase-5 sGC Soluble guanylate cyclase NO Nitric oxide RhoA The Ras homolog family member A ROCK Rho kinase ERAs Endothelin receptor antagonists PDE5i Phosphodiesterase-5 inhibitors SDF Sildenafl TAD Tadalafl FAD Fasudil MCT Monocrotaline EndoMT Endothelial-to-mesenchymal transition NPs Nanoparticles PLGA Poly-lactic/glycolic acid MMAD Mass median aerodynamic diameter RCRPC Respirable controlled-release polymeric colloids Cmax Maximum Plasma Concentration Tmax Time to reach maximum plasma concentration AUC0‐t Area under the plasma concentration–time curve from time zero to time t P(VS-VA)-gPLGA Poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly (lactide-co-glycolide) BALF Bronchoalveolar lavage fuid MOFs Metal-organic frameworks DSPE-PEG 1,2-Distearoyl-sn-glycero-3-phosphoethanolamineN-[methoxy (polyethylene glycol)] HPAH High pulmonary blood fow–associated pulmonary hypertension ELPCs Endothelial-like progenitor cells EPCs Endothelial progenitor cells BPS Beraprost PLA Poly(lactide) SuHx Sugen–hypoxia–normoxia Lips Liposomes EPR The enhanced permeability and retention efect LNPs Liposomal nanoparticles MRI Magnetic resonance imaging RVSP Right ventricular systolic pressure DOTAP 1,2-di-(9Z-octadecenoyl)-3-trimethylammoniumpropane ID1 Diferentiation 1 OVA Ovalbumin PDTC Pyrrolidine dithiocarbamate SA Stearic acid Canadian Respiratory Journal, 2026 15 of 23 7503, 2026, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1155/carj/8046858 by IN A SP - N E PA L , W iley O nline L ibrary on [10/04/2026]. ..
Liposomes:Article Title: Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.
Article Snippet: .. Nomenclature PAH Pulmonary arterial hypertension TGF-β Transforming growth factor beta BMPR2 Bone morphogenetic protein receptor type II PH Pulmonary hypertension nano-DDS Nanoparticle-mediated drug delivery systems ELPCs Endothelial-like progenitor cells mPAP Mean pulmonary artery pressure PASMCs Pulmonary artery smooth muscle cells ET-1 Endothelin-1 PDE5 Phosphodiesterase-5 sGC Soluble guanylate cyclase NO Nitric oxide RhoA The Ras homolog family member A ROCK Rho kinase ERAs Endothelin receptor antagonists PDE5i Phosphodiesterase-5 inhibitors SDF Sildenafl TAD Tadalafl FAD Fasudil MCT Monocrotaline EndoMT Endothelial-to-mesenchymal transition NPs Nanoparticles PLGA Poly-lactic/glycolic acid MMAD Mass median aerodynamic diameter RCRPC Respirable controlled-release polymeric colloids Cmax Maximum Plasma Concentration Tmax Time to reach maximum plasma concentration AUC0‐t Area under the plasma concentration–time curve from time zero to time t P(VS-VA)-gPLGA Poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly (lactide-co-glycolide) BALF Bronchoalveolar lavage fuid MOFs Metal-organic frameworks DSPE-PEG 1,2-Distearoyl-sn-glycero-3-phosphoethanolamineN-[methoxy (polyethylene glycol)] HPAH High pulmonary blood fow–associated pulmonary hypertension ELPCs Endothelial-like progenitor cells EPCs Endothelial progenitor cells BPS Beraprost PLA Poly(lactide) SuHx Sugen–hypoxia–normoxia Lips Liposomes EPR The enhanced permeability and retention efect LNPs Liposomal nanoparticles MRI Magnetic resonance imaging RVSP Right ventricular systolic pressure DOTAP 1,2-di-(9Z-octadecenoyl)-3-trimethylammoniumpropane ID1 Diferentiation 1 OVA Ovalbumin PDTC Pyrrolidine dithiocarbamate SA Stearic acid Canadian Respiratory Journal, 2026 15 of 23 7503, 2026, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1155/carj/8046858 by IN A SP - N E PA L , W iley O nline L ibrary on [10/04/2026]. ..
Permeability:Article Title: Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.
Article Snippet: .. Nomenclature PAH Pulmonary arterial hypertension TGF-β Transforming growth factor beta BMPR2 Bone morphogenetic protein receptor type II PH Pulmonary hypertension nano-DDS Nanoparticle-mediated drug delivery systems ELPCs Endothelial-like progenitor cells mPAP Mean pulmonary artery pressure PASMCs Pulmonary artery smooth muscle cells ET-1 Endothelin-1 PDE5 Phosphodiesterase-5 sGC Soluble guanylate cyclase NO Nitric oxide RhoA The Ras homolog family member A ROCK Rho kinase ERAs Endothelin receptor antagonists PDE5i Phosphodiesterase-5 inhibitors SDF Sildenafl TAD Tadalafl FAD Fasudil MCT Monocrotaline EndoMT Endothelial-to-mesenchymal transition NPs Nanoparticles PLGA Poly-lactic/glycolic acid MMAD Mass median aerodynamic diameter RCRPC Respirable controlled-release polymeric colloids Cmax Maximum Plasma Concentration Tmax Time to reach maximum plasma concentration AUC0‐t Area under the plasma concentration–time curve from time zero to time t P(VS-VA)-gPLGA Poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly (lactide-co-glycolide) BALF Bronchoalveolar lavage fuid MOFs Metal-organic frameworks DSPE-PEG 1,2-Distearoyl-sn-glycero-3-phosphoethanolamineN-[methoxy (polyethylene glycol)] HPAH High pulmonary blood fow–associated pulmonary hypertension ELPCs Endothelial-like progenitor cells EPCs Endothelial progenitor cells BPS Beraprost PLA Poly(lactide) SuHx Sugen–hypoxia–normoxia Lips Liposomes EPR The enhanced permeability and retention efect LNPs Liposomal nanoparticles MRI Magnetic resonance imaging RVSP Right ventricular systolic pressure DOTAP 1,2-di-(9Z-octadecenoyl)-3-trimethylammoniumpropane ID1 Diferentiation 1 OVA Ovalbumin PDTC Pyrrolidine dithiocarbamate SA Stearic acid Canadian Respiratory Journal, 2026 15 of 23 7503, 2026, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1155/carj/8046858 by IN A SP - N E PA L , W iley O nline L ibrary on [10/04/2026]. ..
Magnetic Resonance Imaging:Article Title: Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.
Article Snippet: .. Nomenclature PAH Pulmonary arterial hypertension TGF-β Transforming growth factor beta BMPR2 Bone morphogenetic protein receptor type II PH Pulmonary hypertension nano-DDS Nanoparticle-mediated drug delivery systems ELPCs Endothelial-like progenitor cells mPAP Mean pulmonary artery pressure PASMCs Pulmonary artery smooth muscle cells ET-1 Endothelin-1 PDE5 Phosphodiesterase-5 sGC Soluble guanylate cyclase NO Nitric oxide RhoA The Ras homolog family member A ROCK Rho kinase ERAs Endothelin receptor antagonists PDE5i Phosphodiesterase-5 inhibitors SDF Sildenafl TAD Tadalafl FAD Fasudil MCT Monocrotaline EndoMT Endothelial-to-mesenchymal transition NPs Nanoparticles PLGA Poly-lactic/glycolic acid MMAD Mass median aerodynamic diameter RCRPC Respirable controlled-release polymeric colloids Cmax Maximum Plasma Concentration Tmax Time to reach maximum plasma concentration AUC0‐t Area under the plasma concentration–time curve from time zero to time t P(VS-VA)-gPLGA Poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly (lactide-co-glycolide) BALF Bronchoalveolar lavage fuid MOFs Metal-organic frameworks DSPE-PEG 1,2-Distearoyl-sn-glycero-3-phosphoethanolamineN-[methoxy (polyethylene glycol)] HPAH High pulmonary blood fow–associated pulmonary hypertension ELPCs Endothelial-like progenitor cells EPCs Endothelial progenitor cells BPS Beraprost PLA Poly(lactide) SuHx Sugen–hypoxia–normoxia Lips Liposomes EPR The enhanced permeability and retention efect LNPs Liposomal nanoparticles MRI Magnetic resonance imaging RVSP Right ventricular systolic pressure DOTAP 1,2-di-(9Z-octadecenoyl)-3-trimethylammoniumpropane ID1 Diferentiation 1 OVA Ovalbumin PDTC Pyrrolidine dithiocarbamate SA Stearic acid Canadian Respiratory Journal, 2026 15 of 23 7503, 2026, 1, D ow nloaded from https://onlinelibrary.w iley.com /doi/10.1155/carj/8046858 by IN A SP - N E PA L , W iley O nline L ibrary on [10/04/2026]. ..
|
